

Molecular and Cellular Characterization of the Membrane Alzheimer's Disease

Neurobiology of Aging

18, 415-421

DOI: [10.1016/s0197-4580\(97\)00042-0](https://doi.org/10.1016/s0197-4580(97)00042-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Alzheimer's β -amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. <i>Brain Research</i> , 1998, 807, 110-117.	1.1	109
2	Expression of complement C4 and C9 genes by human astrocytes. <i>Brain Research</i> , 1998, 809, 31-38.	1.1	42
3	The importance of inflammatory mechanisms in Alzheimer disease. <i>Experimental Gerontology</i> , 1998, 33, 371-378.	1.2	325
4	Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions. <i>Journal of Neuroscience Research</i> , 1998, 54, 1-6.	1.3	171
5	Expression and regulation of complement C1q by human THP-1-derived macrophages. <i>Molecular and Chemical Neuropathology</i> , 1998, 34, 197-218.	1.0	31
6	Pro-inflammatory complement activation by the $A\beta$ peptide of Alzheimer's disease is biologically significant and can be blocked by vaccinia virus complement control protein. <i>Neurobiology of Aging</i> , 1998, 19, 619-627.	1.5	44
7	The contribution of inflammation to acute and chronic neurodegeneration. <i>Research in Immunology</i> , 1998, 149, 721-725.	0.9	33
8	ALZHEIMER'S DISEASE: Genetic Studies and Transgenic Models. <i>Annual Review of Genetics</i> , 1998, 32, 461-493.	3.2	384
9	Inhibition of Complement as a Therapeutic Approach in Inflammatory Central Nervous System (CNS) Disease. <i>Molecular Medicine</i> , 1999, 5, 569-582.	1.9	42
10	COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 1521-1536.	1.9	51
11	Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. <i>Brain Research</i> , 1999, 833, 297-301.	1.1	60
12	A unifying hypothesis of Alzheimer's disease. II. Pathophysiological processes. <i>Human Psychopharmacology</i> , 1999, 14, 525-581.	0.7	27
13	Nonsteroidal Anti-Inflammatory Drugs and Alzheimer's Disease. <i>CNS Drugs</i> , 1999, 11, 207-224.	2.7	10
14	Emerging strategies for the treatment of Alzheimer's disease at the Millennium. <i>Expert Opinion on Emerging Drugs</i> , 1999, 4, 35-86.	1.1	1
15	The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. <i>Neurobiology of Aging</i> , 1999, 20, 297-304.	1.5	44
16	Up-Regulated Production and Activation of the Complement System in Alzheimer's Disease Brain. <i>American Journal of Pathology</i> , 1999, 154, 927-936.	1.9	300
17	The Presence of Isoaspartic Acid in β -Amyloid Plaques Indicates Plaque Age. <i>Experimental Neurology</i> , 1999, 157, 277-288.	2.0	55
18	Increased Complement Biosynthesis By Microglia and Complement Activation on Neurons in Huntington's Disease. <i>Experimental Neurology</i> , 1999, 159, 362-376.	2.0	280

#	ARTICLE	IF	CITATIONS
19	Inflammation of the brain in Alzheimer's disease: implications for therapy. <i>Journal of Leukocyte Biology</i> , 1999, 65, 409-415.	1.5	192
20	New Anti-inflammatory Treatment Strategy in Alzheimer's Disease. <i>The Japanese Journal of Pharmacology</i> , 2000, 82, 85-94.	1.2	52
21	Complement components of the innate immune system in health and disease in the CNS. <i>Immunopharmacology</i> , 2000, 49, 171-186.	2.0	324
22	The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2000, 105, 124-130.	1.1	78
23	Expression of complement messenger RNAs by human endothelial cells. <i>Brain Research</i> , 2000, 871, 1-6.	1.1	20
24	Deficiency of Complement Defense Protein CD59 May Contribute to Neurodegeneration in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2000, 20, 7505-7509.	1.7	127
25	Complement Component C1q Modulates the Phagocytosis of A β by Microglia. <i>Experimental Neurology</i> , 2000, 161, 127-138.	2.0	115
26	The cause of neuronal degeneration in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2000, 60, 139-165.	2.8	226
27	Inflammation and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2000, 21, 383-421.	1.5	4,069
28	The role of complement in Alzheimer's disease pathology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000, 1502, 158-171.	1.8	84
29	TREATMENT OF ALZHEIMER'S DISEASE. <i>Neurologic Clinics</i> , 2000, 18, 807-827.	0.8	34
30	Cellular and molecular mechanisms of Alzheimer's disease inflammation. , 2001, , 3-49.		0
31	Inflammation, autotoxicity and Alzheimer disease. <i>Neurobiology of Aging</i> , 2001, 22, 799-809.	1.5	452
32	Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. <i>Neurobiology of Aging</i> , 2001, 22, 849-861.	1.5	83
33	Complement activation by neurofibrillary tangles in Alzheimer's disease. <i>Neuroscience Letters</i> , 2001, 305, 165-168.	1.0	153
34	Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. <i>Brain Research Reviews</i> , 2001, 35, 73-96.	9.1	284
35	Chronic inflammation in Alzheimer's disease offers therapeutic opportunities. <i>Expert Review of Neurotherapeutics</i> , 2001, 1, 53-60.	1.4	14
36	Molecular and cellular mediators of Alzheimer's disease inflammation. <i>Journal of Alzheimer's Disease</i> , 2001, 3, 131-157.	1.2	48

#	ARTICLE	IF	CITATIONS
37	Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia. <i>Archives of Gerontology and Geriatrics</i> , 2001, 33, 13-28.	1.4	62
38	Induction of complement C9 messenger RNAs in human neuronal cells by inflammatory stimuli: relevance to neurodegenerative disorders. <i>Experimental Gerontology</i> , 2001, 36, 1179-1188.	1.2	13
39	The Alzheimer's A β -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11830-11835.	3.3	424
40	Complement Activation in Chromosome 13 Dementias. <i>Journal of Biological Chemistry</i> , 2002, 277, 49782-49790.	1.6	59
41	Detection and Analysis of Synaptosis. , 2002, , 177-203.		0
42	Interleukin-6 and risk of cognitive decline. <i>Neurology</i> , 2002, 59, 371-378.	1.5	482
43	Cyclooxygenase as a Target for the Antiamyloidogenic Activities of Nonsteroidal Anti-Inflammatory Drugs in Alzheimer's Disease. <i>NeuroSignals</i> , 2002, 11, 293-297.	0.5	13
44	Amyloid β -peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 193-201.	1.2	155
46	Inflammation in Neurodegenerative Disease—A Double-Edged Sword. <i>Neuron</i> , 2002, 35, 419-432.	3.8	1,075
47	Fleeting Activation of Ionotropic Glutamate Receptors Sensitizes Cortical Neurons to Complement Attack. <i>Neuron</i> , 2002, 36, 363-374.	3.8	26
48	The possible role of complement activation in Alzheimer disease. <i>Trends in Molecular Medicine</i> , 2002, 8, 519-523.	3.5	79
49	Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1627-1656.	6.6	126
50	Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated A β (1-42) injections in the rat. <i>Brain Research</i> , 2002, 954, 1-10.	1.1	55
51	The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. <i>Lancet Neurology</i> , The, 2002, 1, 279-284.	4.9	188
52	Microglia and inflammatory mechanisms in the clearance of amyloid β peptide. <i>Glia</i> , 2002, 40, 260-269.	2.5	350
53	Development of antiinflammatory therapy for Alzheimer's disease. <i>Drug Development Research</i> , 2002, 56, 421-427.	1.4	6
54	Anti-inflammatory agents in Alzheimer's disease. <i>Current Neurology and Neuroscience Reports</i> , 2002, 2, 405-409.	2.0	19
55	Local Neuroinflammation and the Progression of Alzheimer's Disease. <i>Journal of NeuroVirology</i> , 2002, 8, 529-538.	1.0	225

#	ARTICLE	IF	CITATIONS
56	Roles of the Complement System in Human Neurodegenerative Disorders. <i>Molecular Neurobiology</i> , 2002, 25, 001-018.	1.9	69
57	A Role for NOX NADPH Oxidases in Alzheimer's Disease and Other Types of Dementia?. <i>IUBMB Life</i> , 2003, 55, 307-313.	1.5	103
58	Inhibition of C1q- β -amyloid binding protects hippocampal cells against complement mediated toxicity. <i>Journal of Neuroimmunology</i> , 2003, 137, 12-18.	1.1	24
59	Expression of complement messenger RNAs and proteins by human oligodendroglial cells. <i>Glia</i> , 2003, 42, 417-423.	2.5	83
60	Activation of Complement in the Central Nervous System. <i>Annals of the New York Academy of Sciences</i> , 2003, 992, 56-71.	1.8	212
61	Yin and Yang: complement activation and regulation in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2003, 70, 463-472.	2.8	89
62	Inflammatory processes in Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 741-749.	2.5	445
63	Is there a future for vaccination as a treatment for Alzheimer's disease?. <i>Neurobiology of Aging</i> , 2003, 24, 391-395.	1.5	39
64	Biological markers for therapeutic trials in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 521-536.	1.5	249
65	Complement C5a Receptor-Mediated Signaling May Be Involved in Neurodegeneration in Alzheimer's Disease. <i>Journal of Immunology</i> , 2003, 170, 5764-5771.	0.4	68
66	Scintigraphic visualization of inflammation in neurodegenerative disorders. <i>Nuclear Medicine Communications</i> , 2003, 24, 209-221.	0.5	8
67	Formation of Complement Membrane Attack Complex in Mammalian Cerebral Cortex Evokes Seizures and Neurodegeneration. <i>Journal of Neuroscience</i> , 2003, 23, 955-960.	1.7	133
68	Specificity of mechanisms for plaque removal after $A\beta$ immunotherapy for Alzheimer disease. <i>Nature Medicine</i> , 2004, 10, 117-118.	15.2	48
69	Reply to "Specificity of mechanisms for plaque removal after $A\beta$ immunotherapy for Alzheimer disease". <i>Nature Medicine</i> , 2004, 10, 118-119.	15.2	12
70	Inflammation and the Degenerative Diseases of Aging. <i>Annals of the New York Academy of Sciences</i> , 2004, 1035, 104-116.	1.8	441
71	Peripheral Treatment with Enoxaparin, a Low Molecular Weight Heparin, Reduces Plaques and $A\beta$ Accumulation in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2004, 24, 4181-4186.	1.7	158
72	Activation of Complement Pathways after Contusion-Induced Spinal Cord Injury. <i>Journal of Neurotrauma</i> , 2004, 21, 1831-1846.	1.7	94
73	Human oligodendroglial cells express low levels of C1 inhibitor and membrane cofactor protein mRNAs. <i>Journal of Neuroinflammation</i> , 2004, 1, 17.	3.1	6

#	ARTICLE	IF	CITATIONS
74	Using animal models to determine the significance of complement activation in Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2004, 1, 18.	3.1	13
75	Complement C1q expression induced by A β in rat hippocampal organotypic slice cultures. <i>Experimental Neurology</i> , 2004, 185, 241-253.	2.0	30
76	Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. <i>Experimental Neurology</i> , 2004, 188, 52-64.	2.0	102
77	CCAAT/enhancer binding protein β (C/EBP β) expression and elevation in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, 991-999.	1.5	76
78	Early complement activation increases in the brain in some aged normal subjects. <i>Neurobiology of Aging</i> , 2004, 25, 1001-1007.	1.5	17
79	Terminal Complement Complex: Regulation of Formation and Pathophysiological Functions. , 2004, , 97-127.		8
80	Chronic intracerebroventricular infusion of lipopolysaccharide: effects of ibuprofen treatment and behavioural and histopathological correlates. <i>Behavioural Pharmacology</i> , 2005, 16, 531-541.	0.8	21
81	The role of group I metabotropic glutamate receptors in neuronal excitotoxicity in Alzheimer's disease. <i>Neurotoxicity Research</i> , 2005, 7, 125-141.	1.3	34
82	Altered Cytokine and Acute Phase Response Protein Levels in the Blood of Children with Downs Syndrome: Relationship with Dementia of Alzheimer's Type. <i>International Journal of Immunopathology and Pharmacology</i> , 2005, 18, 165-172.	1.0	54
83	Evidence that immunoglobulin-positive neurons in Alzheimer's disease are dying via the classical antibody-dependent complement pathway. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2005, 20, 144-150.	0.9	34
84	Add Alzheimer's disease to the list of autoimmune diseases. <i>Medical Hypotheses</i> , 2005, 64, 458-463.	0.8	103
85	The role of inflammation in Alzheimer's disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 289-305.	1.2	627
86	Is there a Future for Cyclo-Oxygenase Inhibitors in Alzheimer's Disease?. <i>CNS Drugs</i> , 2006, 20, 85-98.	2.7	22
87	Amyloid- β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients. <i>American Journal of Pathology</i> , 2006, 169, 1048-1063.	1.9	196
88	Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study. <i>Journal of Neuroinflammation</i> , 2006, 3, 29.	3.1	110
89	A Hundred Years of Alzheimer's Disease Research. <i>Neuron</i> , 2006, 52, 3-13.	3.8	427
90	Microglia Activation in the Brain as Inflammatory Biomarker of Alzheimer's Disease Neuropathology and Clinical Dementia. <i>Disease Markers</i> , 2006, 22, 95-102.	0.6	100
91	Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 271-276.	1.2	225

#	ARTICLE	IF	CITATIONS
92	A Perspective on Inflammation in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2000, 924, 132-135.	1.8	64
93	Dynamic Expression of the Membrane Attack Complex (MAC) of the Complement System in Failing Human Myocardium. <i>American Journal of Cardiology</i> , 2006, 97, 1626-1629.	0.7	18
94	Inflammation in Alzheimer's disease. <i>Clinical Neuroscience Research</i> , 2006, 6, 247-260.	0.8	23
95	Cardiovascular Disease Could Be Contained Based on Currently Available Data!. <i>Dose-Response</i> , 2006, 4, dose-response.0.	0.7	2
96	Impaired Volume Regulation is the Mechanism of Excitotoxic Sensitization to Complement. <i>Journal of Neuroscience</i> , 2006, 26, 10177-10187.	1.7	7
97	The Double-Edged Flower: Roles of Complement Protein C1q in Neurodegenerative Diseases. , 2006, 586, 153-176.		32
98	Systemic and Acquired Immune Responses in Alzheimer's Disease. <i>International Review of Neurobiology</i> , 2007, 82, 205-233.	0.9	88
99	Phagocytosis of Amyloid- β and Inflammation: Two Faces of Innate Immunity in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2007, 11, 457-463.	1.2	105
100	Blood-Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy. <i>Cell Transplantation</i> , 2007, 16, 285-299.	1.2	277
101	NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. <i>Neurobiology of Aging</i> , 2007, 28, 639-647.	1.5	454
102	Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 295-303.	21.5	293
103	Complement component C1q inhibits β -amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. <i>Journal of Neurochemistry</i> , 2008, 104, 696-707.	2.1	88
104	Inflammatory processes in Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2007, 184, 69-91.	1.1	664
105	The APP family of proteins: similarities and differences. <i>Biochemical Society Transactions</i> , 2007, 35, 416-420.	1.6	117
106	Disifin (Sodium tosylchloramide) and Toll-like receptors (TLRs): evolving importance in health and diseases. <i>Journal of Industrial Microbiology and Biotechnology</i> , 2007, 34, 751-762.	1.4	8
107	Heat Shock Proteins and Amateur Chaperones in Amyloid-Beta Accumulation and Clearance in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2007, 35, 203-216.	1.9	105
108	Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 720-726.	1.1	73
109	Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2008, 106, 2080-2092.	2.1	111

#	ARTICLE	IF	CITATIONS
110	The complement cascade: Yinâ€“Yang in neuroinflammation â€“ neuroâ€“protection and â€“degeneration. <i>Journal of Neurochemistry</i> , 2008, 107, 1169-1187.	2.1	152
111	Neuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease. <i>Archives of Medical Research</i> , 2008, 39, 1-16.	1.5	315
112	Inflamming as a prodrome to Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2008, 5, 51.	3.1	258
113	Plaque complement activation and cognitive loss in Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2008, 5, 9.	3.1	57
115	Altered Function of Factor I Caused by Amyloid Î²: Implication for Pathogenesis of Age-Related Macular Degeneration from Drusen. <i>Journal of Immunology</i> , 2008, 181, 712-720.	0.4	79
116	The Inflammatory Response in Alzheimer's Disease. <i>Journal of Periodontology</i> , 2008, 79, 1535-1543.	1.7	76
117	Inflammatory Aspects of Alzheimer Disease and Other Neurodegenerative Disorders. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 359-369.	1.2	215
118	Chronic Inflammation and Amyloidogenesis in Alzheimer's Disease -- Role of Spirochetes1. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 381-391.	1.2	136
119	Alzheimer's Disease: Another Target for Heparin Therapy. <i>Scientific World Journal</i> , The, 2009, 9, 891-908.	0.8	42
120	Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administred in Alzheimers Disease. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2009, 8, 85-100.	1.1	10
121	Treatment with a C5aR Antagonist Decreases Pathology and Enhances Behavioral Performance in Murine Models of Alzheimerâ€™s Disease. <i>Journal of Immunology</i> , 2009, 183, 1375-1383.	0.4	229
122	PKR, the double stranded RNAâ€“dependent protein kinase as a critical target in Alzheimer's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1476-1488.	1.6	39
123	The Role of Neuroimmunomodulation in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2009, 1153, 240-246.	1.8	206
124	Immune Activation in Brain Aging and Neurodegeneration: Too Much or Too Little?. <i>Neuron</i> , 2009, 64, 110-122.	3.8	594
125	Inflammation in Alzheimer's disease: Amyloid-Î² oligomers trigger innate immunity defence via pattern recognition receptors. <i>Progress in Neurobiology</i> , 2009, 87, 181-194.	2.8	310
126	Expression of complement system components during aging and amyloid deposition in APP transgenic mice. <i>Journal of Neuroinflammation</i> , 2009, 6, 35.	3.1	90
127	Neuroinflammatory processes in Alzheimerâ€™s disease. <i>Journal of Neural Transmission</i> , 2010, 117, 919-947.	1.4	380
128	The Role of the Complement System and the Activation Fragment C5a in the Central Nervous System. <i>NeuroMolecular Medicine</i> , 2010, 12, 179-192.	1.8	136

#	ARTICLE	IF	CITATIONS
129	Why Pleiotropic Interventions are Needed for Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2010, 41, 392-409.	1.9	141
130	The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. <i>Trends in Genetics</i> , 2010, 26, 84-93.	2.9	122
131	Neuroglia in neurodegeneration. <i>Brain Research Reviews</i> , 2010, 63, 189-211.	9.1	247
132	Neuroinflammation, Microglia and Implications for Anti-Inflammatory Treatment in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-9.	1.1	93
133	Microglial Immunoreceptor Tyrosine-Based Activation and Inhibition Motif Signaling in Neuroinflammation. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-7.	1.1	61
134	Microarray Analysis Identifies Changes in Inflammatory Gene Expression in Response to Amyloid- β^2 Stimulation of Cultured Human Retinal Pigment Epithelial Cells. , 2010, 51, 1151.		82
135	The Role of the Classical Complement Cascade in Synapse Loss During Development and Glaucoma. <i>Advances in Experimental Medicine and Biology</i> , 2010, 703, 75-93.	0.8	51
136	Complement receptor 3 (CD11b/CD18) is implicated in the elimination of β^2 -amyloid peptides. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 115-122.	1.0	26
137	Complement in the brain. <i>Molecular Immunology</i> , 2011, 48, 1592-1603.	1.0	345
138	Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease. <i>Current Opinion in Neurobiology</i> , 2011, 21, 920-928.	2.0	85
139	Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2011, 8, 4.	3.1	76
140	Prevention of the β^2 -amyloid peptide-induced inflammatory process by inhibition of double-stranded RNA-dependent protein kinase in primary murine mixed co-cultures. <i>Journal of Neuroinflammation</i> , 2011, 8, 72.	3.1	49
141	Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. <i>Journal of Neuroinflammation</i> , 2011, 8, 90.	3.1	273
142	Big MAC attack in osteoarthritis. <i>Science-Business EXchange</i> , 2011, 4, 1311-1311.	0.0	0
143	Emerging roles of pathogens in Alzheimer disease. <i>Expert Reviews in Molecular Medicine</i> , 2011, 13, e30.	1.6	162
144	Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006346-a006346.	2.9	786
145	Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. <i>Journal of Neuroinflammation</i> , 2012, 9, 179.	3.1	423
146	Fibrinogen and Altered Hemostasis in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 599-608.	1.2	136

#	ARTICLE	IF	CITATIONS
147	The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. <i>Neurobiology of Aging</i> , 2012, 33, 437-456.	1.5	220
148	Elevated Angiopoietin-1 Serum Levels in Patients with Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-5.	1.1	14
149	Deficiency of complement component 5 ameliorates glaucoma in DBA/2J mice. <i>Journal of Neuroinflammation</i> , 2013, 10, 76.	3.1	83
150	Intravenous immunoglobulin and Alzheimer's disease: what now?. <i>Journal of Neuroinflammation</i> , 2013, 10, 70.	3.1	44
151	Complement activation fragment C5a receptors, CD88 and C5L2, are associated with neurofibrillary pathology. <i>Journal of Neuroinflammation</i> , 2013, 10, 25.	3.1	33
152	The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. <i>Acta Neuropathologica</i> , 2013, 126, 479-497.	3.9	366
153	What does complement do in Alzheimer's disease? Old molecules with new insights. <i>Translational Neurodegeneration</i> , 2013, 2, 21.	3.6	58
154	White Matter Injury Due to Experimental Chronic Cerebral Hypoperfusion Is Associated with C5 Deposition. <i>PLoS ONE</i> , 2013, 8, e84802.	1.1	23
155	Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?. <i>Journal of Neuroinflammation</i> , 2014, 11, 198.	3.1	8
156	Neuroinflammation in Alzheimer's Disease. , 2014, , 161-177.		1
157	The innate and adaptive immunological aspects in neurodegenerative diseases. <i>Journal of Neuroimmunology</i> , 2014, 269, 1-8.	1.1	37
158	Alzheimer's Silent Partner: Cerebral Amyloid Angiopathy. <i>Translational Stroke Research</i> , 2014, 5, 330-337.	2.3	21
159	The role of glial cells and the complement system in retinal diseases and Alzheimer's disease: common neural degeneration mechanisms. <i>Experimental Brain Research</i> , 2014, 232, 3363-3377.	0.7	16
160	Hypertension and Inflammation in Alzheimer's Disease: Close Partners in Disease Development and Progression!. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 331-343.	1.2	45
161	Epistasis analysis links immune cascades and cerebral amyloidosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 227.	3.1	10
162	DBA/2J Genetic Background Exacerbates Spontaneous Lethal Seizures but Lessens Amyloid Deposition in a Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2015, 10, e0125897.	1.1	27
163	Immune Responses in Neurodegenerative Diseases. <i>Kathmandu University Medical Journal</i> , 2015, 12, 67-76.	0.1	7
164	The Role of Inflammation in Alzheimer's Disease. <i>Current Topics in Neurotoxicity</i> , 2015, , 313-336.	0.4	2

#	ARTICLE	IF	CITATIONS
165	<sc>Arizona <sc>Study of <sc>ging and <sc>eurodegenerative <sc>isorders and <sc>rain and <sc>ody <sc>onation <sc>rogram. <i>Neuropathology</i> , 2015, 35, 354-389.	0.7	336
166	TYROBP in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2015, 51, 820-826.	1.9	79
167	Remarkable Activation of the Complement System and Aberrant Neuronal Localization of the Membrane Attack Complex in the Brain Tissues of Scrapie-Infected Rodents. <i>Molecular Neurobiology</i> , 2015, 52, 1165-1179.	1.9	24
168	Antimicrobial Peptides and Complement in Neonatal Hypoxia-Ischemia Induced Brain Damage. <i>Frontiers in Immunology</i> , 2015, 6, 56.	2.2	56
169	Oxidative Stress Events and Neuronal Dysfunction in Alzheimer's Disease: Focus on APE1/Ref-1-Mediated Survival Strategies. , 2015, , 175-207.		9
170	Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 707-716.	1.2	41
171	Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 853-857.	1.2	169
172	Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms. <i>Alzheimer's and Dementia</i> , 2017, 13, 1397-1409.	0.4	38
173	C1q: A fresh look upon an old molecule. <i>Molecular Immunology</i> , 2017, 89, 73-83.	1.0	188
174	Inflammation Friend or Foe?. , 2017, , 192-241.		2
175	Multi-Faceted Role of Melatonin in Neuroprotection and Amelioration of Tau Aggregates in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1481-1493.	1.2	34
176	Intersection of pathological tau and microglia at the synapse. <i>Acta Neuropathologica Communications</i> , 2019, 7, 109.	2.4	119
177	The complement cascade in Alzheimer's disease: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2021, 26, 5532-5541.	4.1	51
178	Emerging Roles of Complement in Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2019, 10, 573.	1.3	63
179	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 82.	3.0	51
180	Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System. <i>Frontiers in Immunology</i> , 2019, 10, 362.	2.2	148
181	A REVIEW ON MICROGLIA: ROLE IN NEUROINFLAMMATION, SCREENING MODELS AND THERAPEUTIC STRATEGIES FOR TREATMENT. <i>International Research Journal of Pharmacy</i> , 2019, 10, 11-15.	0.0	2
182	Complement dysregulation in the central nervous system during development and disease. <i>Seminars in Immunology</i> , 2019, 45, 101340.	2.7	85

#	ARTICLE	IF	CITATIONS
183	Complement-Mediated Events in Alzheimer's Disease: Mechanisms and Potential Therapeutic Targets. <i>Journal of Immunology</i> , 2020, 204, 306-315.	0.4	61
184	Study of the complement activation by amyloid aggregates of smooth muscle titin in vitro. <i>Journal of Immunoassay and Immunochemistry</i> , 2020, 41, 132-143.	0.5	2
185	The effect of insomnia on development of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2020, 17, 289.	3.1	48
186	The good, the bad, and the opportunities of the complement system in neurodegenerative disease. <i>Journal of Neuroinflammation</i> , 2020, 17, 354.	3.1	133
187	Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics. <i>Pharmaceuticals</i> , 2020, 13, 341.	1.7	15
188	Alzheimer's Disease and Specialized Pro-Resolving Lipid Mediators: Do MaR1, RvD1, and NPD1 Show Promise for Prevention and Treatment?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5783.	1.8	19
189	Complement System Activation by Amyloid Aggregates of A β (1-40) and A β (1-42) Peptides: Facts and Hypotheses. <i>Biophysics (Russian Federation)</i> , 2020, 65, 18-21.	0.2	3
190	Astrocyte- and Neuron-Derived Extracellular Vesicles from Alzheimer's Disease Patients Effect Complement-Mediated Neurotoxicity. <i>Cells</i> , 2020, 9, 1618.	1.8	52
191	TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 724.	2.2	174
192	Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases. <i>Immunology</i> , 2021, 162, 160-178.	2.0	12
193	The Impact of Complement Genes on the Risk of Late-Onset Alzheimer's Disease. <i>Genes</i> , 2021, 12, 443.	1.0	18
194	Association between dementia and systemic rheumatic disease: A nationwide population-based study. <i>PLoS ONE</i> , 2021, 16, e0248395.	1.1	10
195	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. <i>Biomolecules</i> , 2021, 11, 600.	1.8	16
196	Amyloids: The History of Toxicity and Functionality. <i>Biology</i> , 2021, 10, 394.	1.3	12
197	Importance of extracellular vesicle secretion at the blood-cerebrospinal fluid interface in the pathogenesis of Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 143.	2.4	30
198	Central Nervous System Diseases and Inflammation. , 2008, , 153-174.		4
199	Inflammatory Processes Exacerbate Degenerative Neurological Disorders. , 2009, , 117-124.		4
200	Complement Involvement in Neovascular Ocular Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2012, 946, 161-183.	0.8	38

#	ARTICLE	IF	CITATIONS
201	Complement, neuroinflammation and neuronal degeneration in Alzheimer disease. , 2001, , 15-20.		1
202	Potential Beneficial Effects of a Diet with Walnuts in Aging and Alzheimer's Disease. , 2012, , 239-252.		3
203	Stability and bioactivity of chitosan as a transfection agent in primary human cell cultures: A case for chitosan-only controls. Carbohydrate Polymers, 2018, 180, 376-384.	5.1	10
205	Innate Immunity, Local Inflammation, and Degenerative Disease. Science of Aging Knowledge Environment: SAGE KE, 2002, 2002, 3re-3.	0.9	49
206	Immunotherapy for Alzheimer's Disease. Science of Aging Knowledge Environment: SAGE KE, 2004, 2004, pe29-pe29.	0.9	7
207	CCAAT-Enhancer Binding Protein- β Expression and Elevation in Alzheimer's Disease and Microglial Cell Cultures. PLoS ONE, 2014, 9, e86617.	1.1	38
208	Molecular identification of protein kinase C beta in Alzheimer's disease. Aging, 2020, 12, 21798-21808.	1.4	8
209	Innate Immunity in Alzheimer's Disease: A Complex Affair. CNS and Neurological Disorders - Drug Targets, 2013, 12, 593-607.	0.8	69
210	The role of immunity and neuroinflammation in genetic predisposition and pathogenesis of Alzheimer's disease. AIMS Genetics, 2015, 02, 230-249.	1.9	2
211	Organization of Inflammatory Processes in Alzheimer's Disease. Research and Perspectives in Neurosciences, 2000, , 1-7.	0.4	0
212	Amyloid β peptide interactions with the classical pathway of complement. , 2001, , 105-119.		0
213	The role of cyclooxygenase in Alzheimer's disease neurodegeneration. , 2001, , 197-207.		0
214	Complement mediator systems in Alzheimer's disease. , 2001, , 89-103.		0
215	Processo Inflamatório e Neuroimunomodulação na Doença de Alzheimer. Revista Neurociências, 2011, 19, 300-313.	0.0	0
216	Neuroinflammation, Alzheimer Disease, and Other Aging Disorders. , 2007, , 149-166.		0
217	Aging and Cognitive Decline: Neuroprotective Strategies. , 2007, , 245-268.		0
218	Roles of Innate Immunity and Inflammation in the Aging Brain. Oxidative Stress and Disease, 2011, , .	0.3	0
219	Innate Inflammatory Reaction of the Brain in Alzheimer Disease. McGill Journal of Medicine, 1997, 3, .	0.1	1

#	ARTICLE	IF	CITATIONS
221	Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease. <i>Molecular Medicine</i> , 1999, 5, 569-82.	1.9	16
222	Serine protease HtrA1 accumulates in corneal transforming growth factor beta induced protein (TGFBIp) amyloid deposits. <i>Molecular Vision</i> , 2013, 19, 861-76.	1.1	26
225	Complement membrane attack complex is related with immune-mediated necrotizing myopathy. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 4143-9.	0.5	9
226	Complement as a powerful "influencer" in the brain during development, adulthood and neurological disorders. <i>Advances in Immunology</i> , 2021, 152, 157-222.	1.1	11
227	Neuropsychiatric disorders: An immunological perspective. <i>Advances in Immunology</i> , 2021, 152, 83-155.	1.1	10
228	Genetic Insights into the Impact of Complement in Alzheimer's Disease. <i>Genes</i> , 2021, 12, 1990.	1.0	14
229	Microglial Responses in Alzheimer's Disease: Recent Studies in Transgenic Mice and Alzheimer's Disease Brains. , 0, , 267-282.		0
230	Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	19